Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma. - Wikidata - awgldk - TriplyDB

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

http://www.wikidata.org/entity/Q33430690

about

Immuno-targeting the multifunctional CD38 using nanobody Carfilzomib boosted combination therapy for relapsed multiple myeloma Adipose, Bone, and Myeloma: Contributions from the Microenvironment.Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents.Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.

P2860

Q36959363-7A0BE667-5B1D-41E3-B9ED-74A40A51CC94 Q37652953-428B8E53-7983-4ABA-9827-8B8159BC00DA Q38876521-C2D4E0C6-1558-4063-8B37-63F1FFD99674 Q41559549-C08E31C7-27CA-48B9-ACAE-334C7657F51E Q47162496-108C391C-8B89-4650-9110-FE6E1B48ADFE Q47240693-FCE5718E-6D10-4682-BAF3-53EE6DE24090

P2860

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

http://www.wikidata.org/entity/Q33430690

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

@ast

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

@en

type

label

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

@ast

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

@en

prefLabel

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

@ast

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

@en

P1433

Q33430690-D3382EB4-ADE6-40E2-8E0B-DE9429FE4CCA

P1476

Q33430690-FA0C08E5-C24D-4FA2-AA8D-7AA0B6F39B48

P2093

Q33430690-61E067E4-3A0D-493C-98C0-8A086831E779

P2860

Q33430690-03DC6B56-6E30-4E17-860E-73A0706445A9

Q33430690-14D7364F-29FA-4E62-A7FF-99938FA511E1

Q33430690-336E2DEB-DCE9-40B4-AD37-92A471F7E13D

Q33430690-5BED6E50-E290-4CC1-87C1-83975AFFCEF6

Q33430690-729EC35C-ADD2-49E3-9543-B8E90513D232

Q33430690-7C3192B6-7706-41EB-ACF1-672D6C541FBE

Q33430690-87B9F875-D9D9-4EE2-B02E-CF5C8CB49997

Q33430690-8A575160-08C8-44F1-8603-D4D83BB12367

Q33430690-8C5F57AA-1CDA-4776-A476-D598BCC5AEC3

Q33430690-8EFD4379-1E2E-4011-AA0E-EE044B20E655

P2888

Q33430690-B67AC20D-87F7-4F87-AADF-6D9D6514DC7A

P304

Q33430690-C8D62362-ED0D-440E-998A-830A898B73EE

P31

Q33430690-29709CD0-CF51-4B42-96A3-DD4BD7FD831A

P356

Q33430690-D44823AE-A6AB-4A37-8FC4-035EBF8ACCD2

P433

Q33430690-33B597AA-BD73-4DEA-9494-07840318107A

P478

Q33430690-EBB0026D-019D-47FF-9A6D-A0A389FA7E4A

P577

Q33430690-E3E5B4E1-0D2F-43BA-A542-4246EC333F34

P6179

Q33430690-7F66CCD4-8627-4A47-A5E1-705ED9EEDDE6

P698

Q33430690-ED7BF37F-09A1-4B9F-B4F6-17063A1F99B7

P356

S11523-016-0428-7

P1433

Targeted oncology

P1476

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.

@en

P2093

Sheridan M Hoy

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Current treatment landscape for relapsed and/or refractory multiple myeloma.

P2888

s11523-016-0428-7

P304

255-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-016-0428-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049217761

http://www.w3.org/2001/XMLSchema#string

P698

26972294

http://www.w3.org/2001/XMLSchema#string